Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern

NCT03478982 is registered in ClinicalTrials.gov with Engage Therapeutics, Inc. as lead sponsor.

NCT NCT03478982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03478982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern
Lead sponsor
Engage Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 16, 2018
Completion date
January 4, 2020
Enrollment
156 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy